<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E65D5505-6DF9-4801-9019-B9EDE5D0EE5D"><gtr:id>E65D5505-6DF9-4801-9019-B9EDE5D0EE5D</gtr:id><gtr:name>University Medical Center Gronigen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB"><gtr:id>60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB</gtr:id><gtr:name>Brigham and Women's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7F06A235-D83F-4EDF-A8A3-9216E21C9752"><gtr:id>7F06A235-D83F-4EDF-A8A3-9216E21C9752</gtr:id><gtr:name>Charles University</gtr:name><gtr:address><gtr:line1>Ke Karlovu 3</gtr:line1><gtr:postCode>121 16 Pra</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Czech Republic</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/33DA74F3-4EF3-4BB0-BB91-18DD7C501907"><gtr:id>33DA74F3-4EF3-4BB0-BB91-18DD7C501907</gtr:id><gtr:name>Sheba Medical Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/040001EB-7CD7-4B8C-998C-7097FA7B9B98"><gtr:id>040001EB-7CD7-4B8C-998C-7097FA7B9B98</gtr:id><gtr:name>Mount Sinai Hospital (Canada)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3CA539EA-7DA5-4676-822A-580EB6E26FF1"><gtr:id>3CA539EA-7DA5-4676-822A-580EB6E26FF1</gtr:id><gtr:name>ANGLE</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Surgery</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E65D5505-6DF9-4801-9019-B9EDE5D0EE5D"><gtr:id>E65D5505-6DF9-4801-9019-B9EDE5D0EE5D</gtr:id><gtr:name>University Medical Center Gronigen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB"><gtr:id>60B71C12-9A8A-4C09-B2C3-88FC51ECE8FB</gtr:id><gtr:name>Brigham and Women's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7F06A235-D83F-4EDF-A8A3-9216E21C9752"><gtr:id>7F06A235-D83F-4EDF-A8A3-9216E21C9752</gtr:id><gtr:name>Charles University</gtr:name><gtr:address><gtr:line1>Ke Karlovu 3</gtr:line1><gtr:postCode>121 16 Pra</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Czech Republic</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/33DA74F3-4EF3-4BB0-BB91-18DD7C501907"><gtr:id>33DA74F3-4EF3-4BB0-BB91-18DD7C501907</gtr:id><gtr:name>Sheba Medical Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/040001EB-7CD7-4B8C-998C-7097FA7B9B98"><gtr:id>040001EB-7CD7-4B8C-998C-7097FA7B9B98</gtr:id><gtr:name>Mount Sinai Hospital (Canada)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3CA539EA-7DA5-4676-822A-580EB6E26FF1"><gtr:id>3CA539EA-7DA5-4676-822A-580EB6E26FF1</gtr:id><gtr:name>ANGLE</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FC01333C-41FD-4946-B81E-E26D053A43F1"><gtr:id>FC01333C-41FD-4946-B81E-E26D053A43F1</gtr:id><gtr:firstName>Siong-seng</gtr:firstName><gtr:surname>Liau</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002543"><gtr:id>F9580532-AAEC-446B-8755-DF969D7D2D0D</gtr:id><gtr:title>Dissecting roles of High Mobility Group A1 (HMGA1) pathway in pancreatic adenocarcinoma progression through in vivo monitoring of cancer dynamics...</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1002543</gtr:grantReference><gtr:abstractText>Pancreatic cancer is the deadliest of human cancers. Effective treatment and early detection strategies for this cancer is desperately needed. Our project aims to understand the process of pancreatic cancer progression, in the hope of identifying new ways to treat and detect this cancer. By focussing on the roles of high mobility group A1 (HMGA1) gene, we may identify novel pathways for rational therapy of pancreatic cancer. Our project may lead to the development of imaging-based early detection strategies.</gtr:abstractText><gtr:technicalSummary>Introduction: Pancreatic ductal adenocarcinoma (PDA) is the 5th leading cause of cancer-related death in the UK. To improve our understanding of this deadly cancer, we have engineered the KPC mouse harbouring conditional mutant alleles in K-ras and p53 genes targeted exclusively to pancreas, which recapitulates PDA (100% penetrance). The HMGA1 gene encodes for chromatin-associated proteins which regulate a constellation of pro-oncogenic genes. Our data suggests that HMGA1 is overexpressed in &amp;gt;90% of PDAs. Previously, we showed that HMGA1 promotes malignant phenotype in PDA cells. We now propose to dissect the roles of HMGA1 in PDA progression.

Project aims: We have formulated 3 independent study aims.

Aim-1: To examine the process of PDA progression in real-time by in vivo introduction of pro-oncogenic HMGA1 coexpressed with a fluorescent reporter 
We hypothesize that in vivo introduction of HMGA1 gene will accelerate the process of cancer progression in KPC murine pancreas. We will introduce the HMGA1 gene coexpressed with a reporter gene (i.e. eGFP) into the pancreas of KPC mouse. At the site of HMGA1-eGFP introduction, the developing PDA will be labeled with eGFP which allows imaging studies (intravital multiphoton microscopy, bioluminescence) to track tumour progression, at an unprecedented single-cell level in vivo. 

Aim-2: To evaluate if HMGA1 promotes initiation and maintenance of PDA using a conditional transgenic mouse model
We will perform a genetic dissection of HMGA1 functions using 3 novel targeted mouse models: conditional knock-in (CKI-1 &amp;amp;-2) and conditional knockout (CKO) HMGA1 mice. We will assess the dependence of PDA initiation and maintenance on HMGA1 expression. Co-operative roles of HMGA1 with K-ras and p53 will be elucidated by crossing the HMGA1 transgenic mice (CKI-1, CKI-2, CKO) with KPC mice. 

Aim-3: To perform a genome-wide analysis of HMGA1 transcriptional and signaling networks in PDA to identify novel biomarkers and therapeutic targets
Using chromatin immunoprecipitation sequencing (ChIP-Seq), microarray expression profiling and constructed PanIN-PDA tissue microarrays, we will systematically examine integrated HMGA1-related pathways to identify ?direct? and ?indirect? targets of HMGA1. Harnessing bioinformatic strategies, we will focus on clinically-relevant candidate pathways of functional importance to identify novel biomarkers and therapeutic targets. 

Medical Opportunities: Our research strategy of characterising the mechanisms driving PDA progression will yield rational therapies and new biomarkers for early detection of this deadly cancer.</gtr:technicalSummary><gtr:fund><gtr:end>2018-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>964685</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sheba Medical Centre</gtr:collaboratingOrganisation><gtr:country>Israel, State of</gtr:country><gtr:department>Institute of Oncology</gtr:department><gtr:description>Collaboration with Dr Talia Golan</gtr:description><gtr:id>7F4C82C5-11F5-4E15-896F-86A144F5FB13</gtr:id><gtr:impact>Work currently in progress. Output will be anticipated in 12 months.</gtr:impact><gtr:outcomeId>58bd6aba221e20.74270980-1</gtr:outcomeId><gtr:partnerContribution>Dr Golan has identified pancreatic cancer patient/s with inherited PALB2 gene mutation in Israel.</gtr:partnerContribution><gtr:piContribution>Analyses of PALB2-mutant pancreatic cancer patients.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mount Sinai Hospital (Canada)</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Samuel Lunenfeld Research Institute</gtr:department><gtr:description>Collaboration with Prof Steven Gallinger</gtr:description><gtr:id>7DF4E3FF-6915-40F8-92D0-D2D8BB523057</gtr:id><gtr:impact>Development of a collaborative project involving the sequencing of pancreatic cancer specimens to identify somatic mutations involved in disease progression.</gtr:impact><gtr:outcomeId>Bxzp5mnb71r-1</gtr:outcomeId><gtr:partnerContribution>The use of biological samples (i.e. DNA and tumour specimens) as part of the Ontario Pancreatic Cancer Study.</gtr:partnerContribution><gtr:piContribution>Development of transgenic mouse model of pancreatic cancer.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Collaboration with Professor Stefan Boeck</gtr:description><gtr:id>C21026AF-EAF0-44DE-8D51-9B1A558B7FB1</gtr:id><gtr:impact>Work currently in progress. Output will be anticipated in 12 months.</gtr:impact><gtr:outcomeId>58bd6b93a59814.19343686-1</gtr:outcomeId><gtr:partnerContribution>Prof Boeck has identified pancreatic cancer patient with inherited PALB2 gene mutation in Germany.</gtr:partnerContribution><gtr:piContribution>Analyses of PALB2-mutant pancreatic cancer patient.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brigham and Women's Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Surgery</gtr:department><gtr:description>Collaboration with Prof Edward Whang</gtr:description><gtr:id>04D19825-C463-4FE1-9CFA-644C748DA26C</gtr:id><gtr:impact>Ongoing work.</gtr:impact><gtr:outcomeId>EZbNiQQ5zxC-1</gtr:outcomeId><gtr:partnerContribution>Provision of human pancreatic cancer tissue microarray with associated clinical outcome data.</gtr:partnerContribution><gtr:piContribution>Analysis of biomarkers and status of signaling pathways in pancreatic cancer tissues.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ANGLE</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Parsotix Team</gtr:department><gtr:description>Collaboration with Angle Plc.</gtr:description><gtr:id>BF3FDB4C-40A1-4B67-B1AC-E82BBA33E54E</gtr:id><gtr:impact>Ongoing</gtr:impact><gtr:outcomeId>KHMfSyyUrUS-1</gtr:outcomeId><gtr:partnerContribution>Collaboratively, we are assisting with the intellectual and scientific development of this novel patented Parstotix Circulating Tumour Cell (CTC) capture device (based on separation by physical characteristics of CTCs) and the analyser system. We will assist in the development of this system into one with clinical utility in cancer patients, specifically in pancreatic cancer.</gtr:partnerContribution><gtr:piContribution>Collaboratively, we are assisting with the intellectual and scientific development of this novel patented Parstotix Circulating Tumour Cell (CTC) capture device (based on separation by physical characteristics of CTCs) and the analyser system. We will assist in the development of this system into one with clinical utility in cancer patients, specifically in pancreatic cancer.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK Cambridge Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Dr Doug Fearon</gtr:description><gtr:id>D654B57A-168C-4B22-9270-89558B1C0E8A</gtr:id><gtr:impact>Surgical oncology and cancer immunology</gtr:impact><gtr:outcomeId>5449307244b0e0.23979536-1</gtr:outcomeId><gtr:partnerContribution>Cancer immunology</gtr:partnerContribution><gtr:piContribution>Collaborating as a surgeon scientist</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Erasmus University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Department of Experimental Surgical Oncology</gtr:department><gtr:description>Collaboration with Dr Timo Ten Hagen</gtr:description><gtr:id>9D20D277-6CC7-43CC-BAF0-5F2769D48A7F</gtr:id><gtr:impact>This included a collaborative visit to Dr Ten Hagen's laboratory in Erasmus Medical Centre.</gtr:impact><gtr:outcomeId>HTLoXhKPD3L-1</gtr:outcomeId><gtr:partnerContribution>Training and expert advice on the use of window chambers in mouse models of pancreatic cancer.</gtr:partnerContribution><gtr:piContribution>Development of imaging-based transgenic mouse model of pancreatic cancer.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medical Genetics</gtr:department><gtr:description>Collaboration with Dr Marc Tischkowitz</gtr:description><gtr:id>EA071148-9FB8-4E60-A33F-39DCA461B05A</gtr:id><gtr:impact>Multiple discussions including the use of biological specimens from Dr Tischkowitz's collaborators in Canada.</gtr:impact><gtr:outcomeId>AaRB6eBHpFk-1</gtr:outcomeId><gtr:partnerContribution>Collaborative discussion based on Dr Tischkowitz's previous work on fanconi anaemia genes in pancreatic cancer.</gtr:partnerContribution><gtr:piContribution>Development of transgenic mouse models of pancreatic cancer based on impaired fanconi anaemia genes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Addenbrooke's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Histopathology Department</gtr:department><gtr:description>Collaboration With Dr Rebecca Brais</gtr:description><gtr:id>F887907E-9EB6-4C87-88CE-CD649425E9FB</gtr:id><gtr:impact>Histopathology and Surgery.</gtr:impact><gtr:outcomeId>PkMtYn9co5u-1</gtr:outcomeId><gtr:partnerContribution>Provision of pancreatic cancer tissue microarray and the use of the Department of Histopathology Research Core for IHC.</gtr:partnerContribution><gtr:piContribution>Analysis of pancreatic cancer tissue microarray.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>McGill University</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Collaboration with Dr George Zogopoulous</gtr:description><gtr:id>8992DAD7-2230-4C3F-ACE2-1B0413AEFFD3</gtr:id><gtr:impact>Ongoing work</gtr:impact><gtr:outcomeId>56d73bcec63e31.76301139-1</gtr:outcomeId><gtr:partnerContribution>Dr Zogopoulous' team has identified patients with PALB2 germline mutations with pancreatic cancer. This collaboration will provide us with human tissues in this unique subgroup of patients for further analyses.</gtr:partnerContribution><gtr:piContribution>We have developed novel transgenic mouse models of Palb2 gene in pancreatic cancer.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charles University</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:department>First Faculty of Medicine</gtr:department><gtr:description>Collaboration with Dr Marketa Janatova</gtr:description><gtr:id>ECB3AD39-76FA-4976-82E0-E8308ED8D7DE</gtr:id><gtr:impact>Work currently in progress. Output will be anticipated in 12 months.</gtr:impact><gtr:outcomeId>58bd69b3553339.12836587-1</gtr:outcomeId><gtr:partnerContribution>Dr Janatova has the largest series of pancreatic cancer patients with inherited PALB2 gene mutation.</gtr:partnerContribution><gtr:piContribution>Analyses of PALB2-mutant pancreatic cancer patients.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Medical Center Gronigen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Collaboration with Dr Go Van Dam</gtr:description><gtr:id>EF47D810-52D1-40F0-9C1E-ECFC613B0F67</gtr:id><gtr:impact>Awaiting outcome of grant application</gtr:impact><gtr:outcomeId>EF1hB8a6EvL-1</gtr:outcomeId><gtr:partnerContribution>Collaboratively submitted a Stand Up to Cancer Dream Team grant (Dutch Cancer Society - American Association of Cancer Research). Title of grant submitted: Optical guided perSonalized Pancreatic dUctal adenocaRcinoma treatment (SPUR)</gtr:partnerContribution><gtr:piContribution>Collaboratively submitted a Stand Up to Cancer Dream Team grant (Dutch Cancer Society - American Association of Cancer Research). Title of grant submitted: Optical guided perSonalized Pancreatic dUctal adenocaRcinoma treatment (SPUR)</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Production of Cambridge Cancer Centre Early Detection Infographics</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>403D2BAE-FADF-4836-9A03-E40003DC00B7</gtr:id><gtr:impact>Input into the production of Early Cancer Detection Infographics to give physical scientists an overview of the development, progression and current standard of care for pancreatic cancer. This will help to identify areas where there may be opportunities for research to aid early detection of pancreatic cancer.</gtr:impact><gtr:outcomeId>58bd6e5650ddd8.95532385</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pump Priming Grant</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Royal College of Surgeons of England</gtr:fundingOrg><gtr:id>7856B89C-FFA5-4123-8451-10C2308B46BC</gtr:id><gtr:outcomeId>56d73c4ac73070.08983216</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pancreatic Society of Great Britain and Ireland Pump-priming Research Grant</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Pancreatic Society of Great Britain and Ireland (PanSoc)</gtr:fundingOrg><gtr:id>FC8F67B4-7751-4D68-99A7-D0EE3DCD3C64</gtr:id><gtr:outcomeId>JfoVkSTnD3i</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Early Career Centenary Award</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Hutchison/MRC Research Centre</gtr:fundingOrg><gtr:id>BBCCDCB9-648E-49C2-9EA7-8775A276998C</gtr:id><gtr:outcomeId>fM825akzVLF</gtr:outcomeId><gtr:sector>Multiple</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Small Research Grant</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>The Royal College of Surgeons of Edinburgh</gtr:fundingOrg><gtr:id>A329C718-5571-4511-A1FF-474D159AC047</gtr:id><gtr:outcomeId>mvW4jYmDeKe</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RCS Edinburgh Small Research Grant</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>The Royal College of Surgeons of Edinburgh</gtr:fundingOrg><gtr:id>30226E35-26A8-4193-90A9-28EB2AF09E4A</gtr:id><gtr:outcomeId>58bd6c5c7564c8.78273271</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Starter Grant</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>C4829DBB-E79E-4E93-BA1D-719CBEA2A56D</gtr:id><gtr:outcomeId>RvjdPLpp91a</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RCS Edinburgh Small Research Grant</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>The Royal College of Surgeons of Edinburgh</gtr:fundingOrg><gtr:id>321A56C2-B7FE-4D4D-9001-5E17BAB1013C</gtr:id><gtr:outcomeId>pnvPmgzwd7x</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Utilisation of recent publication as basis of new European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines Indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an Option for Post-Chemotherapy Treatment of Intrahepatic Cholangiocarcinoma (iCCA)</gtr:guidelineTitle><gtr:id>A684F7D4-96EE-4C5A-AB1B-875DDEB5F699</gtr:id><gtr:impact>The following excerpt was obtained from ESMO:
''The ESMO inclusion of SIRT for the treatment of iCCA was based on ESMO's review of a pooled analysis of 12 studies totalling 298 patients that was published in the European Journal of Surgical Oncology in 2015, by Dr D. Al-Adra et al. These data showed a median overall survival of 15.5 months and treatment response rate of 28% in patients treated with SIRT. In addition, the new ESMO guidelines on biliary cancers call special attention to a subset of studies in the pooled SIRT analysis, stating that importantly, 7/73 (10%) patients in three selected studies were converted to resectable disease, highlighting the importance of reassessment of patients in the multidisciplinary team in the event of a good response to any treatment.&amp;quot;</gtr:impact><gtr:outcomeId>58bd70af54a4e0.34243050</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.prnewswire.co.uk/news-releases/new-european-society-of-medical-oncology-esmo-biliary-cancer-guidelines-indicate-selective-internal-radiation-therapy-sirt-with-y-90-microspheres-as-an-option-for-post-chemotherapy-treatment-of-intrahepatic-cholangiocarcinoma-596614121.html</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>We have retrospectively collected the data for a large cohort of patients who had undergone pancreatic resection for malignancies at Cambridge HPB Surgical Unit over the last 10 years, with the primary aim of identifying the survival outcome and factors that influence survivals.</gtr:description><gtr:id>A86928A1-162A-4168-9338-2CAFBAC93EF9</gtr:id><gtr:impact>Research manuscript is current in progress.</gtr:impact><gtr:outcomeId>58bd73077fb415.80189256</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Database of post-resection pancreatic cancer patients in East Anglia with linked clinical and survival outcome based on UK Cancer Registry data</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Mouse models of pancreatic cancer based on transgenic expression of mutant Aurora A kinase. These models have been successfully developed.</gtr:description><gtr:id>EB4B5784-AA38-4C88-A925-0842C37C2278</gtr:id><gtr:impact>Once developed, these mouse models will facilitate the study of gene functions in the development of pancreatic cancer.</gtr:impact><gtr:outcomeId>XLxgdjhQ78c</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Transgenic mouse models of pancreatic cancer based on Aurora A kinase mutation</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mouse models of pancreatic cancer based on mutant Palb2 gene. These models have been successfully developed.</gtr:description><gtr:id>00C0A171-6E8C-4F69-A92B-903D42ECE09F</gtr:id><gtr:impact>nce developed, these mouse models will facilitate the study of gene functions in the development of pancreatic cancer.</gtr:impact><gtr:outcomeId>58bd719171c536.56063208</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Transgenic mouse models of pancreatic cancer based on Palb2 mutation</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0E331663-3144-4ACF-8A7E-F15213183870</gtr:id><gtr:title>Development of a Prognostic Model That Predicts Survival After Pancreaticoduodenectomy for Ampullary Cancer.</gtr:title><gtr:parentPublicationTitle>Pancreas</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/799d19a6e9d71f59325403101c609139"><gtr:id>799d19a6e9d71f59325403101c609139</gtr:id><gtr:otherNames>Feretis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0885-3177</gtr:issn><gtr:outcomeId>5a9faab51549b6.46562672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F175B405-8DC2-4CDA-85A0-4BA6965D2A36</gtr:id><gtr:title>Molecular pathogenesis of hepatic adenomas and its implications for surgical management.</gtr:title><gtr:parentPublicationTitle>Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98019bd83987f0f3f3287870f38d7adc"><gtr:id>98019bd83987f0f3f3287870f38d7adc</gtr:id><gtr:otherNames>Liau SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1091-255X</gtr:issn><gtr:outcomeId>pm_13529_29_23835731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5341297-CB3C-4CEF-B5F2-56F75A197554</gtr:id><gtr:title>Extra-hepatic portal vein aneurysm: A case report, overview of the literature and suggested management algorithm.</gtr:title><gtr:parentPublicationTitle>International journal of surgery case reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/390bef56ea3015f3d5835b5b16a76ef4"><gtr:id>390bef56ea3015f3d5835b5b16a76ef4</gtr:id><gtr:otherNames>Ma R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2210-2612</gtr:issn><gtr:outcomeId>pm_13529_29_22922358</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7144414B-AA9E-4F8A-BD94-50B976107769</gtr:id><gtr:title>Cancer genetics: a primer for surgeons.</gtr:title><gtr:parentPublicationTitle>The Surgical clinics of North America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93c34555486f2d77ba14a9b8e4d78c4d"><gtr:id>93c34555486f2d77ba14a9b8e4d78c4d</gtr:id><gtr:otherNames>Benson JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0039-6109</gtr:issn><gtr:outcomeId>pm_13529_19_18672136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7946B82D-BC50-4604-AC00-D0AE630DE585</gtr:id><gtr:title>High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98019bd83987f0f3f3287870f38d7adc"><gtr:id>98019bd83987f0f3f3287870f38d7adc</gtr:id><gtr:otherNames>Liau SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1479-666X</gtr:issn><gtr:outcomeId>pm_13529_19_19848064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30AAE3D6-3E1D-4EB0-BF94-FB820ECC25C7</gtr:id><gtr:title>Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis.</gtr:title><gtr:parentPublicationTitle>European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52414071e60d7812c01e652b483d1258"><gtr:id>52414071e60d7812c01e652b483d1258</gtr:id><gtr:otherNames>Al-Adra DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0748-7983</gtr:issn><gtr:outcomeId>54492e3279d455.74970121</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCC67B31-9E24-4388-BBC7-989605E8A67C</gtr:id><gtr:title>Negative predictive value of drain amylase concentration for development of pancreatic fistula after pancreaticoduodenectomy.</gtr:title><gtr:parentPublicationTitle>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74b0058e72067fa9128866329cd70105"><gtr:id>74b0058e72067fa9128866329cd70105</gtr:id><gtr:otherNames>Zelga P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1424-3903</gtr:issn><gtr:outcomeId>56d73aaae49cb5.61933968</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74227D36-24FB-4805-ADDA-8BBB176402CE</gtr:id><gtr:title>Molecular pathology of pancreatic cancer</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc37576cc11fd77ebd7adac73450ded8"><gtr:id>bc37576cc11fd77ebd7adac73450ded8</gtr:id><gtr:otherNames>Siong-Seng Liau and David Tuveson</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>978-0-521-87662-9</gtr:isbn><gtr:outcomeId>54492d5aee3cb3.73748883</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C70F35A-EB18-4AE7-94F1-8011BB5F6BEE</gtr:id><gtr:title>Laparoscopic adrenalectomy: auditing the 10 year experience of a single centre.</gtr:title><gtr:parentPublicationTitle>The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61bfba4a69bdf49ad04771f581475c26"><gtr:id>61bfba4a69bdf49ad04771f581475c26</gtr:id><gtr:otherNames>Ali JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1479-666X</gtr:issn><gtr:outcomeId>pm_13529_29_22959160</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A1ABD6F-E654-4279-9932-9367C025A5C3</gtr:id><gtr:title>Audit of local recurrence following breast conservation surgery with 5-mm target margin and hypofractionated 40-Gray breast radiotherapy for invasive breast cancer.</gtr:title><gtr:parentPublicationTitle>Annals of the Royal College of Surgeons of England</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98019bd83987f0f3f3287870f38d7adc"><gtr:id>98019bd83987f0f3f3287870f38d7adc</gtr:id><gtr:otherNames>Liau SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0035-8843</gtr:issn><gtr:outcomeId>pm_13529_29_20522309</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8B61B57-D4DE-430D-91B8-43536968B792</gtr:id><gtr:title>Incidental non-benign gallbladder histopathology after cholecystectomy in an United Kingdom population: Need for routine histological analysis?</gtr:title><gtr:parentPublicationTitle>World journal of gastrointestinal surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c6fc250b8929b2b3333637f883eb38d"><gtr:id>8c6fc250b8929b2b3333637f883eb38d</gtr:id><gtr:otherNames>Patel K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b856ff33c7f7.15274289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2115F058-1FEB-4F61-8249-9BBFB684792F</gtr:id><gtr:title>Chromosome instability and carcinogenesis: insights from murine models of human pancreatic cancer associated with BRCA2 inactivation.</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1333dc61a50bcdc0960fd1f4abc240f"><gtr:id>d1333dc61a50bcdc0960fd1f4abc240f</gtr:id><gtr:otherNames>Cassidy LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn><gtr:outcomeId>BgMAHZ5wM6s</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27B63352-7A9A-406D-9FC0-8251B66BACC6</gtr:id><gtr:title>The role of surgery in cancer prevention.</gtr:title><gtr:parentPublicationTitle>Current problems in surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ddb15225d9205cab54f1c053d756820"><gtr:id>2ddb15225d9205cab54f1c053d756820</gtr:id><gtr:otherNames>Jatoi I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0011-3840</gtr:issn><gtr:outcomeId>pm_13529_29_20816140</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25E9EC78-2315-45D2-A172-C04B2D692644</gtr:id><gtr:title>Surgical management of hepato-pancreatic metastasis from renal cell carcinoma.</gtr:title><gtr:parentPublicationTitle>World journal of gastrointestinal oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d82259919b6e6f14e344c3527f02c9f"><gtr:id>1d82259919b6e6f14e344c3527f02c9f</gtr:id><gtr:otherNames>Chatzizacharias NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58bd67b3520b94.89349780</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002543</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>